OPKO Health’s (OPK) “Outperform” Rating Reaffirmed at Barrington Research

Barrington Research restated their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a research report released on Wednesday morning,Benzinga reports. They currently have a $2.25 target price on the biotechnology company’s stock.

A number of other research firms have also recently commented on OPK. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, March 3rd. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Price Performance

OPK opened at $1.78 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -9.37 and a beta of 1.70. The firm’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $1.56. OPKO Health has a 1 year low of $0.86 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 67,434 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the purchase, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at approximately $364,745,476.08. The trade was a 0.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 889,971 shares of company stock worth $1,344,442 in the last ninety days. Company insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Intech Investment Management LLC bought a new stake in OPKO Health in the 3rd quarter valued at about $190,000. Integrated Investment Consultants LLC bought a new stake in shares of OPKO Health during the third quarter valued at about $233,000. FMR LLC increased its position in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the period. BNP Paribas Financial Markets increased its position in shares of OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 217,450 shares during the period. Finally, Rubric Capital Management LP increased its position in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. 64.63% of the stock is currently owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.